title: The 2003 Canadian recommendations for dyslipidemia management: revisions are needed.
authors.affiliation: Institute for Clinical Evaluative Sciences, Toronto, Ont. doug.manuel@ices.on.ca
authors.forename: Douglas G
authors.initials: DG
authors.lastname: Manuel
authors.forename: Peter
authors.initials: P
authors.lastname: Tanuseputro
authors.forename: Cameron A
authors.initials: CA
authors.lastname: Mustard
authors.forename: Susan E
authors.initials: SE
authors.lastname: Schultz
authors.forename: Geoffrey M
authors.initials: GM
authors.lastname: Anderson
authors.forename: Sten
authors.initials: S
authors.lastname: Ardal
authors.forename: David A
authors.initials: DA
authors.lastname: Alter
authors.forename: Andreas
authors.initials: A
authors.lastname: Laupacis
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002170:Canada; D008078:Cholesterol, LDL / Q000097:blood; D003327:Coronary Disease / Q000401:mortality / Q000517:prevention & control*; D003362:Cost-Benefit Analysis; D005102:Health Expenditures; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use*; D006949:Hyperlipidemias / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000627:therapeutic use; D008875:Middle Aged; D017410:Practice Guidelines as Topic; D012307:Risk Factors
chemical_list: D008078:Cholesterol, LDL; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D000960:Hypolipidemic Agents